[at Seeking Alpha] – Gilead’s ( GILD ) reluctance to marry its Hep C drug Sovaldi with Bristol-Myers Squibb’s ( BMY ) daclatasvir forced Bristol to take evasive action. Bristol applied to the European Union for approval of …
Read more on … [visit site to read more]
- Company Update (NASDAQ:GILD): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead
- Stock Update: Biogen Idec Inc. (NASDAQ:BIIB) – [video] Biogen CEO: More products, company is focused
- Boeingâ€™s Double Top: Will the company continue to soar?